a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer
Industry Biotechnology
A.I.dvisor indicates that over the last year, FBRX has been loosely correlated with QSI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if FBRX jumps, then QSI could also see price increases.
Ticker / NAME | Correlation To FBRX | 1D Price Change % | ||
---|---|---|---|---|
FBRX | 100% | +3.69% | ||
QSI - FBRX | 39% Loosely correlated | -8.67% | ||
CLNN - FBRX | 32% Poorly correlated | -7.23% | ||
CHRS - FBRX | 30% Poorly correlated | +0.59% | ||
VRCA - FBRX | 26% Poorly correlated | -2.51% | ||
XCUR - FBRX | 25% Poorly correlated | +2.26% | ||
More |